Approach towards immunotherapy for Neurofibromatosis type I

Authors

• S Karmakar
• KM Reilly

Abstract

Neurofibromatosis type I affects 1 individual in 3500. NF1 mutation leads to tumors in nerves that can progress to malignant peripheral nerve sheath tumors (MPNST). Despite much effort to develop therapeutic strategies, currently there are no therapies available to prevent growth and progression of Neurofibromatosis type 1 tumors. How the immune system acts on MPNST has not been fully elucidated yet. Unleashing the cytotoxic ability of the immune system to fight MPNSTs could lead to the development of immunotherapy for MPNST patients. In this current study we are evaluating the ability of male mouse MPNST tumor cells to form tumors in syngeneic immune competent male and female mice to examine the timing of immunological changes during tumor growth. We are also evaluating whether immunological factors are differentially regulated in Nf1-/+ mutant and wild type mice. We will present here the results of our ongoing analysis.

Scientific Focus Area: Immunology

This page was last updated on Friday, March 26, 2021